

## Publication List

(Yusuke Masuo, Ph D.)

- 1) Hasan Alshammari A, Masuo Y, Fujita KI, Shimada K, Iida N, Wakayama T, Kato Y. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition. *Biochem Pharmacol*, 197: 114914, 2022
- 2) Yoshihara M, Mizutani S, Matsumoto K, Kato Y, Masuo Y, Tano S, Mizutani H, Kotani T, Mizutani E, Shibata K, Kajiyama H. Crosstalk between foetal vasoactive peptide hormones and placental aminopeptidases regulates placental blood flow: Its significance in preeclampsia. *Placenta*, 121: 32-39, 2022
- 3) Iida N, Mizukoshi E, Yamashita T, Yutani M, Seishima J, Wang Z, Arai K, Okada H, Yamashita T, Sakai Y, Masuo Y, Agustina R, Kato Y, Fujinaga Y, Oshima M, Honda M, Lebreton F, Gilmore MS, Kaneko S. Chronic liver disease enables gut *Enterococcus faecalis* colonization to promote liver carcinogenesis. *Nat Cancer*, 2: 1039-1054, 2021
- 4) Agustina R, Masuo Y, Kido Y, Shinoda K, Ishimoto T, Kato Y. Identification of food-derived isoflavone sulfates as inhibition markers for intestinal breast cancer resistance proteins. *Drug Metab Dispos*, 49: 972-984, 2021
- 5) Futatsugi A, Masuo Y, Kato Y. Effects of probenecid on hepatic and renal disposition of hexadecanedioate, an endogenous substrate of Organic anion transporting polypeptide 1b in rats. *J Pharm Sci*, 110: 2274-2284, 2021
- 6) Masuo Y, Fujita KI, Mishiro K, Seba N, Kogi T, Okumura H, Matsumoto N, Kunishima M, Kato Y. 6-Hydroxyindole is an endogenous long-lasting OATP1B1 inhibitor elevated in renal failure patients. *Drug Metab Pharmacokinet*, 35: 555-562, 2020
- 7) Nishiyama M, Nakamichi N, Yoshimura T, Masuo Y, Komori T, Ishimoto T, Matsuo JI, Kato Y. Homostachydrine is a xenobiotic substrate of OCTN1/SLC22A4 and potentially sensitizes pentylenetetrazole-induced seizures in mice. *Neurochem Res*, 45: 2664-2678, 2020
- 8) Taguchi T, Masuo Y, Sakai Y, Kato Y. Static model-based assessment of OATP1B1-mediated drug interactions with preincubation-dependent inhibitors based on inactivation and recovery kinetics. *Drug Metab Dispos*, 48: 750-758, 2020
- 9) Nakamichi N, Nakao S, Nishiyama M, Takeda Y, Ishimoto T, Masuo Y, Matsumoto S, Suzuki M, Kato Y. Oral administration of the food derived hydrophilic antioxidant ergothioneine enhances object recognition memory in mice. *Curr Mol Pharmacol*, 14: 220-233, 2021
- 10) Kubota Y, Fujita KI, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Shimada K, Masuo Y, Kato Y, Sasaki Y. Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients. *Clin Pharmacol Ther*, 108: 586-595, 2020
- 11) Taguchi T, Masuo Y, Sakai Y, Kato Y. Short-lasting inhibition of hepatic uptake transporter OATP1B1 by tyrosine kinase inhibitor pazopanib. *Drug Metab Pharmacokinet*, 34: 372-379, 2019
- 12) Hashimoto N, Nakamichi N, Nanmo H, Kimura KI, Masuo Y, Sakai Y, Schinkel AH, Sato S, Soga T, Kato Y. Metabolome analysis reveals dermal histamine accumulation in murine dermatitis provoked by genetic deletion of P-glycoprotein and breast cancer resistance protein. *Pharm Res*, 36: 158, 2019
- 13) Nakamichi N, Matsumoto Y, Kawanishi T, Ishimoto T, Masuo Y, Horikawa M, Kato Y. Maturational characterization of mouse cortical neurons three-dimensionally cultured in functional polymer FP001-containing medium. *Biol Pharm Bull*, 42: 1545-1553, 2019

- 14) Kawanishi T, Arakawa H, **Masuo Y**, Nakamichi N, Kato Y. Bile duct obstruction leads to increased intestinal expression of breast cancer resistance protein with reduced gastrointestinal absorption of imatinib. *J Pharm Sci*, 108: 3130-3137, 2019
- 15) Nakamichi N, Nakao S, **Masuo Y**, Koike A, Matsumura N, Nishiyama M, Al-Shammari AH, Sekiguchi H, Sutoh K, Usumi K, Kato Y. Hydrolyzed salmon milt extract enhances object recognition and location memory through an increase in hippocampal cytidine nucleoside levels in normal mice. *J Med Food*, 22: 408-415, 2019
- 16) Iwase M, Fujita KI, Nishimura Y, Seba N, **Masuo Y**, Ishida H, Kato Y, Kiuchi Y. Pazopanib interacts with irinotecan by inhibiting UGT1A1-mediated glucuronidation, but not OATP1B1-mediated hepatic uptake, of an active metabolite SN-38. *Cancer Chemother Pharmacol*, 83: 993-998, 2019
- 17) Al-Shammari AH, **Masuo Y**, Fujita KI, Yoshikawa Y, Nakamichi N, Kubota Y, Sasaki Y, Kato Y. Influx and efflux transporters contribute to the increased dermal exposure to active metabolite of regorafenib after repeated oral administration in mice. *J Pharm Sci*, 108: 2173-2179, 2019
- 18) Ishimoto T, **Masuo Y**, Kato Y, Nakamichi N. Ergothioneine-induced neuronal differentiation is mediated through activation of S6K1 and neurotrophin 4/5-TrkB signaling in murine neural stem cells. *Cell Signal*, 53: 269-280, 2018
- 19) **Masuo Y**, Ohba Y, Yamada K, Al-Shammari AH, Seba N, Nakamichi N, Ogihara T, Kunishima M, Kato Y. Combination metabolomics approach for identifying endogenous substrates of carnitine/organic cation transporter OCTN1. *Pharm Res*, 35: 224, 2018
- 20) Ellawatty WEA, **Masuo Y**, Fujita KI, Yamazaki E, Ishida H, Arakawa H, Nakamichi N, Abdelwahed R, Sasaki Y, Kato Y. Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib. *Drug Metab Dispos*, 46: 33-40, 2018
- 21) Ishimoto T, Nakamichi N, Nishijima H, **Masuo Y**, Kato Y. Carnitine/organic cation transporter OCTN1 negatively regulates activation in murine cultured microglial cells. *Neurochem Res*, 43: 116-128, 2018
- 22) Takahashi S, Tanaka N, Golla S, Fukami T, Krausz KW, Polunas MA, Weig BC, **Masuo Y**, Xie C, Jiang C, Gonzalez FJ. Farnesoid X receptor protects against low-dose carbon tetrachloride-induced liver injury through the taurocholate-JNK pathway. *Toxicol Sci*, 158: 334-346, 2017
- 23) Fujita KI, **Masuo Y**, Yamazaki E, Shibutani T, Kubota Y, Nakamichi N, Sasaki Y, Kato Y. Involvement of the transporters P-gp and BCRP in dermal distribution of the multi-kinase inhibitor regorafenib and its active metabolites. *J Pharm Sci*, 106: 2632-2641, 2017
- 24) Yamamoto H, Takada T, Yamanashi Y, Ogura M, **Masuo Y**, Harada-Shiba M, Suzuki H. VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body. *Sci Rep*, 7: 633, 2017
- 25) **Masuo Y**, Nagamori S, Hasegawa A, Hayashi K, Isozumi N, Nakamichi N, Kanai Y, Kato Y. Utilization of liver microsomes to estimate hepatic intrinsic clearance of monoamine oxidase substrate drugs in humans. *Pharm Res*, 34: 1233-1243, 2017
- 26) Hashimoto N, Nakamichi N, Yamazaki E, Oikawa M, **Masuo Y**, Schinkel AH, Kato Y. P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids. *Int J Pharm*, 521: 365-373, 2016
- 27) Abouzed TK, Munesue S, Harashima A, **Masuo Y**, Kato Y, Kahilo KK, Yamamoto H, Yamamoto Y. Preventive effect of salicylate and pyridoxamine on diabetic nephropathy. *J Diabetes Res*, 2016: 1786789, 2016
- 28) Nakamichi N, Ishimoto T, Yamauchi Y, **Masuo Y**, Kato Y. Screening to identify multidrug resistance-associated protein inhibitors with neuroblastoma-selective cytotoxicity. *Biol Pharm Bull*, 39: 1638-1645, 2016

- 29) Takahashi S, Fukami T, **Masuo Y**, Brocker CN, Xie C, Krausz KW, Wolf CR, Henderson CJ, Gonzalez FJ. Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. *J Lipid Res*, 57: 2130-2137, 2016
- 30) Futatsugi A, **Masuo Y**, Kawabata S, Nakamichi N, Kato Y. L503F variant of carnitine/organic cation transporter 1 efficiently transports metformin and other biguanides. *J Pharm Pharmacol*, 68: 1160-9, 2016
- 31) Taguchi T, **Masuo Y**, Kogi T, Nakamichi N, Kato Y. Characterization of long-lasting Oatp inhibition by typical inhibitor cyclosporine A and in vitro-in vivo discrepancy in its drug interaction potential in rats. *J Pharm Sci*, 105: 2231-2239, 2016
- 32) Nakamichi N, Nakayama K, Ishimoto T, **Masuo Y**, Wakayama T, Sekiguchi H, Sutoh K, Usumi K, Iseki S, Kato Y. Food-derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts antidepressant effect in mice. *Brain Behav*, 6: e00477, 2016
- 33) Tang Y, **Masuo Y**, Sakai Y, Wakayama T, Sugiura T, Harada R, Futatsugi A, Komura T, Nakamichi N, Sekiguchi H, Sutoh K, Usumi K, Iseki S, Kaneko S, Kato Y. Localization of xenobiotic transporter OCTN1/SLC22A4 in hepatic stellate cells and its protective role in liver fibrosis. *J Pharm Sci*, 105: 1779-1789, 2016
- 34) Fujita K, **Masuo Y**, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y, Kitamura M, Kunishima M, Sasaki Y, Kato Y. Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. *Pharm Res*, 33: 269-282, 2016
- 35) Takada T, Yamanashi Y, Konishi K, Yamamoto T, Toyoda Y, **Masuo Y**, Yamamoto H, Suzuki H. NPC1L1 is a key regulator of intestinal vitamin K absorption and a modulator of warfarin therapy. *Sci Transl Med*, 7: 275ra23, 2015
- 36) Shimizu T, Kijima A, **Masuo Y**, Ishimoto T, Sugiura T, Takahashi S, Nakamichi N, Kato Y. Gene ablation of carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminosalicylate in mice. *Chem Pharm Bull*, 38: 774-780, 2015
- 37) Shimizu T, **Masuo Y**, Takahashi S, Nakamichi N, Kato Y. Organic cation transporter Octn1-mediated uptake of food-derived antioxidant ergothioneine into infiltrating macrophages during intestinal inflammation in mice. *Drug Metab Pharmacokinet*, 30: 231-239, 2015
- 38) Ishimoto T, Nakamichi N, Hosotani H, **Masuo Y**, Sugiura T and Kato Y. Organic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons. *PLoS One*, 9: e89434, 2014
- 39) Takeuchi K, Sugiura T, Matsubara K, Sato R, Shimizu T, **Masuo Y**, Horikawa M, Nakamichi N, Ishiwata N, Kato Y. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in human. *Drug Metab Dispos*, 42: 726-734, 2014
- 40) **Masuo Y**, Ito K, Yamamoto T, Hisaka A, Honma M, Suzuki H. Characterization of inhibitory effect of carbapenem antibiotics on the deconjugation of valproic acid glucuronide. *Drug Metab Dispos*, 38: 1828-1835, 2010